Organogenesis Holdings Inc
NASDAQ:ORGO
Organogenesis Holdings Inc
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
Revenue Beat: Q3 revenue hit $150.5 million, exceeding the high end of guidance, driven by 31% growth in Advanced Wound Care and 25% growth in Surgical & Sports Medicine.
Guidance Raised: Full-year 2025 revenue and profitability guidance raised, with net revenue now expected between $500 million and $525 million and GAAP net income up to $25.4 million.
Medicare Policy Impact: Management highlighted major payment reform by CMS for 2026, which is expected to benefit Organogenesis due to its strong product portfolio and positioning.
Clinical Developments: Mixed results from ReNu's second Phase III trial, but management remains optimistic about FDA approval, with a key meeting scheduled for December.
Margins and ASPs: Gross margins slightly declined to 76%, and management expects average selling prices (ASPs) to fall market-wide in 2026, but higher reimbursement for key products could offset the impact.
